NO20010021L - Trifunksjonelt reagens for konjugering til et biomolekyl - Google Patents

Trifunksjonelt reagens for konjugering til et biomolekyl

Info

Publication number
NO20010021L
NO20010021L NO20010021A NO20010021A NO20010021L NO 20010021 L NO20010021 L NO 20010021L NO 20010021 A NO20010021 A NO 20010021A NO 20010021 A NO20010021 A NO 20010021A NO 20010021 L NO20010021 L NO 20010021L
Authority
NO
Norway
Prior art keywords
biomolecule
reagent
linker
conjugation
moiety
Prior art date
Application number
NO20010021A
Other languages
English (en)
Norwegian (no)
Other versions
NO20010021D0 (no
Inventor
Scott D Wilbur
Bengt E B Sandberg
Original Assignee
Univ Washington Dept Of Radiat
Mitra Medical Technology Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington Dept Of Radiat, Mitra Medical Technology Ab filed Critical Univ Washington Dept Of Radiat
Publication of NO20010021D0 publication Critical patent/NO20010021D0/no
Publication of NO20010021L publication Critical patent/NO20010021L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Optics & Photonics (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20010021A 1998-07-07 2001-01-03 Trifunksjonelt reagens for konjugering til et biomolekyl NO20010021L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/SE1998/001345 WO2000002050A1 (en) 1998-07-07 1998-07-07 Trifunctional reagent for conjugation to a biomolecule
PCT/SE1999/001241 WO2000002051A1 (en) 1998-07-07 1999-07-07 Trifunctional reagent for conjugation to a biomolecule

Publications (2)

Publication Number Publication Date
NO20010021D0 NO20010021D0 (no) 2001-01-03
NO20010021L true NO20010021L (no) 2001-03-07

Family

ID=20410995

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20010021A NO20010021L (no) 1998-07-07 2001-01-03 Trifunksjonelt reagens for konjugering til et biomolekyl

Country Status (9)

Country Link
US (1) US20050271673A1 (de)
EP (1) EP1095274B1 (de)
JP (1) JP2002519440A (de)
AT (1) ATE483162T1 (de)
AU (2) AU8366398A (de)
CA (1) CA2336739A1 (de)
DE (1) DE69942802D1 (de)
NO (1) NO20010021L (de)
WO (2) WO2000002050A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9100142L (sv) 1991-01-17 1992-07-18 Bengt Sandberg En metod och ett system foer foerbaettrad in vivo reducering av diagnostiska och/eller terapeutiska substanser medelst extrakorporeal borttagning, och anvaendandet av naemnda substanser foer detta aendamaal
US20010023288A1 (en) 1999-07-07 2001-09-20 Wilbur D. Scott Trifunctional reagent for conjugation to a biomolecule
DE10012120A1 (de) * 2000-03-13 2001-09-27 Ktb Tumorforschungs Gmbh Therapeutische und diagnostische Ligandensysteme mit Transportmolekülbindenden Eigenschaften und diese enthaltende Arzneimittel
AU2001252978A1 (en) * 2000-03-27 2001-10-08 Zyomyx, Inc. Site-specific, covalent bioconjugation of proteins
SE0002287D0 (sv) * 2000-06-16 2000-06-16 Department Of Radiation Oncolo Biotinderivat
FR2814463B1 (fr) * 2000-09-22 2002-11-15 Sanofi Synthelabo Nouveaux polysaccharides a activite antithrombotique comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine
WO2002030474A1 (en) * 2000-10-12 2002-04-18 Mitra Medical Technology Ab Kit for intraperitoneal administration and extracorpeal removal of a drug
WO2003000201A2 (en) * 2001-06-25 2003-01-03 Drug Innovation & Design, Incorporated Exponential pattern recognition based cellular targeting, compositions, methods and anticancer applications
DE10227599B4 (de) * 2002-06-20 2005-04-28 Proteome Factory Ag Verfahren und Reagenz zur spezifischen Identifizierung und Quantifizierung von einem oder mehreren Proteinen in einer Probe
SE0203731D0 (sv) * 2002-12-13 2002-12-13 Mitra Medical Technology Ab Reagent
CA2509103A1 (en) * 2002-12-13 2004-07-01 Mitra Medical Technology Ab Antilymphoma targeting agents with effector and affinity functions linked by a trifunctional reagent
CA2540131A1 (en) * 2003-10-02 2005-04-14 The General Hospital Corporation Polybiotin compounds for magnetic resonance imagining and drug delivery
US20080267865A1 (en) * 2003-11-28 2008-10-30 Biotech Igg Ab Targeting of Erb Antigens
US20110014151A1 (en) * 2006-01-11 2011-01-20 Biotech Igg Ab Macromolecule conjugate
EP2118127A4 (de) 2007-01-31 2010-12-01 Affymax Inc Linker auf stickstoffbasis zur bindung modifizierender gruppen an polypeptide und andere makromoleküle
KR20100029764A (ko) 2007-05-16 2010-03-17 케이티비 투머포슝스케쉘샤프트 엠비에이치 저점성 안트라사이클린 제제
WO2008145609A1 (en) * 2007-05-25 2008-12-04 Novartis Ag Method of making covalent conjugates with his-tagged proteins
FR2918664B1 (fr) * 2007-07-11 2009-10-02 Commissariat Energie Atomique Reactif pseudo peptidique trifonctionnel, ses utilisations et applications.
FI20090100A0 (fi) * 2009-03-16 2009-03-16 Wallac Oy Biotinidaasimääritys
CN103403011A (zh) 2011-01-31 2013-11-20 Eth苏黎世公司 三官能交联试剂
GB201205360D0 (en) * 2012-03-27 2012-05-09 Univ Edinburgh Biotinidase resistant biotinyl compounds
WO2015148126A1 (en) * 2014-03-12 2015-10-01 Invictus Oncology Pvt. Ltd. Targeted drug delivery through affinity based linkers
KR102656471B1 (ko) * 2015-11-10 2024-04-11 에테하 쭈리히 삼작용성 가교결합 시약
CN106166311B (zh) * 2016-08-30 2018-07-13 张小曦 一种血浆净化系统及其应用
EP3929587A1 (de) * 2020-06-25 2021-12-29 Technische Universität Berlin Vernetzungsreagenz für die biokonjugation zur verwendung bei der proteomik-vernetzung, insbesondere der vernetzungsmassenspektrometrieanalyse

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4877868A (en) * 1986-03-12 1989-10-31 Neorx Corporation Radionuclide antibody coupling
EP0310361A3 (de) * 1987-09-30 1989-05-24 Beckman Instruments, Inc. Aus drei Verzahnungen bestehendes Konjugat und Verfahren zu seiner Verwendung
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
US5310916A (en) * 1988-07-19 1994-05-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Trifunctional agents useful as irreversible inhibitors of A1-adenosine receptors
US5134071A (en) * 1989-02-06 1992-07-28 State University Of New York Polymerization and copolymerization of proteins
DE69034042T2 (de) * 1989-08-02 2003-07-17 Mitra Medical Technology Ab, Lund System zur verwendung in einem verfahren zur therapeutischen und diagnostischen behandlung
US5273743A (en) * 1990-03-09 1993-12-28 Hybritech Incorporated Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
US5124471A (en) * 1990-03-26 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bifunctional dtpa-type ligand
WO1993002105A1 (en) * 1991-07-19 1993-02-04 Hybritech Incorporated Trifunctional compounds having specificity for multi-drug resistant cells
US5541287A (en) * 1992-06-09 1996-07-30 Neorx Corporation Pretargeting methods and compounds
US5578287A (en) * 1992-06-09 1996-11-26 Neorx Corporation Three-step pretargeting methods using improved biotin-active agent
DE4310141A1 (de) * 1993-03-29 1994-10-06 Boehringer Mannheim Gmbh Homobidentale trifunktionelle Linker
US5482698A (en) * 1993-04-22 1996-01-09 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin polymer conjugates
US5739287A (en) * 1994-04-08 1998-04-14 University Of Washington Biotinylated cobalamins
DE69528523T2 (de) * 1994-04-08 2003-06-12 Receptagen Corp., Edmonds Rezeptor modulierendes mitteln und entsprechendes verfahren
US5840880A (en) * 1994-04-08 1998-11-24 Receptagen Corporation Receptor modulating agents
US5686578A (en) * 1994-08-05 1997-11-11 Immunomedics, Inc. Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
AU2052497A (en) * 1996-02-08 1997-08-28 Board Of Regents Of The University Of Washington, The Biotin-containing compounds, biotinylation reagents and methods
US20010023288A1 (en) * 1999-07-07 2001-09-20 Wilbur D. Scott Trifunctional reagent for conjugation to a biomolecule
BR9815493A (pt) * 1997-07-21 2000-10-31 Pharmacia & Upjohn Ab Citólise dirigida de células-alvo, agentes e composições que causam citólise, e compostos que podem ser usados para produzir os agentes

Also Published As

Publication number Publication date
WO2000002050A1 (en) 2000-01-13
EP1095274B1 (de) 2010-09-29
AU5076799A (en) 2000-01-24
US20050271673A1 (en) 2005-12-08
AU8366398A (en) 2000-01-24
DE69942802D1 (de) 2010-11-11
WO2000002051A1 (en) 2000-01-13
NO20010021D0 (no) 2001-01-03
ATE483162T1 (de) 2010-10-15
EP1095274A1 (de) 2001-05-02
CA2336739A1 (en) 2000-01-13
JP2002519440A (ja) 2002-07-02

Similar Documents

Publication Publication Date Title
NO20010021D0 (no) Trifunksjonelt reagens for konjugering til et biomolekyl
DK1053256T3 (da) Antistoffer mod Dødsreceptor 4 (DR4) og anvendelser deraf
WO2002087498A8 (en) Diagnostic imaging compositions, their methods of synthesis and use
CA2090700A1 (en) Modified antibodies with controlled clearance time
DE69926630D1 (de) Antikörper gegen die ed-b domäne von fibronektin, solche antikörper enthaltende konjugate, und deren verwendung zur diagnose und therapie von angiogenese-assoziierten tumoren und krankheiten
BR9508402A (pt) Ligante de união construção de fator de tecido composição farmacêutica kit e uso de um ligante de união
SG149815A1 (en) Monomethylvaline compounds capable of conjugation to ligands
ATE369878T1 (de) Träger-pharmaka-konjugate
TR199902803T2 (xx) VCAM-1' in te�hisinin daralt�lmas� i�in bile�ikler ve metodlar.
KR910005862A (ko) 신규 친수성 유도체, 진단 또는 치료시 그의 응용 그를 함유하는 진단 또는 치료용 키트 및 면역 시약
WO2002087497A3 (en) Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use
DE69516403D1 (de) Photodynamische konjugate mit biozide eigenschaften
SE8701905D0 (sv) A method and a kit for the diagnosis of iga nephropathy
WO2001016184A3 (en) Diagnostic assay for type 2 heparin-induced thrombocytopenia
IE900494L (en) Cross-linked antibodies and processes for their preparation
AU9363398A (en) Hepatitis c receptor protein cd81
CA2366514A1 (en) Diagnostic and therapeutic use of antibodies against the urokinase receptor
ES2092514T3 (es) Conjugados de anticuerpos de dominio variable.
TR200000416T2 (tr) Neisseria loctoferrin bağlayıcı protein.
ATE249243T1 (de) Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat
CA2199145A1 (en) Novel n3s2 chelating ligands optionally radiolabelled with tc or re, useful for diagnostic or therapeutic applications
BR0207327A (pt) Amino derivados de biotina e seus conjugados com agentes quelantes macrocìclicos
FI933506A0 (fi) Bicyklopolyazamakrocyklokarboxylsyrakomplex, konjugat daerav, foerfarande foer deras framstaellning och anvaendning som kontrastmedel
NZ511034A (en) Methods of downmodulating the immune response to therapeutic proteins
EP0569531A4 (de) Stabilisierte antikörperfragmente.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application